Potential for FDA 505(b)(2) regulatory pathway approval and FDA Fast Track designation Advancing Ketamine and KETABET alone or in a microneedle patch for intradermal administration Potential next generation treatment for mental health, neurological and pain disorders TORONTO, June 15, 2021 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM)…


Previous articleField Trip Health Ltd. Announces Completion of DMPK Studies, Engineering Batch for FT-104, Its Novel Psychedelic Compound
Next articleOptimi Health Completes Pre-Clinical Trial Application Meeting